NCT00046748已完成3 期
Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 484
- 主要终点
- Clinically significant asthma exacerbation
研究概览
简要总结
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 12 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •with the diagnosis of allergic asthma >1 year duration who, in addition to the standards of the American Thoracic Society (ATS) meet the following criteria:
- •with a positive prick skin test (diameter of wheal > 3 mm) to at least one perennial allergen (e.g. dust mite, animal dander, cockroaches), within the past 5 years or at Visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study. A RAST test may be performed for patients with a borderline skin prick test result.
- •with total serum IgE level 30 to 700 IU/ml.
- •demonstrating 12% increase in FEV1 over baseline value within 30 minutes of taking up to 4 puffs salbutamol (albuterol) or nebulized salbutamol up to 5mg (or equivalent of alternative B-2 agonist) documented within the past year, at screening, during the run-in period or at baseline prior to randomization.
- •with FEV1 40-80% of predicted normal value for the patient (demonstrable at least 6 hours after short acting B-2 agonist use or 12 hours after long acting B-2 agonist use) at baseline.
- •who have either experienced at least two independent asthma exacerbations requiring unscheduled clinical intervention with a systemic corticosteroid in the past year.
- •been admitted to hospital (including intensive care unit) or received emergency room (including urgent care centers) treatment in the past 12 months for an asthma exacerbation, which in accordance with the GINA guidelines met all of the following criteria for a severe exacerbation:
- •PEF or FEV1< 60% of predicted/personal best, or patient is too breathless to provide PEF.
- •No improvement after initial treatment and therefore requiring repeated treatment with inhaled B-2 agonist (high dose, spacer or nebulized).
- •Requiring treatment with systemic corticosteroids
- •receiving high dose inhaled corticosteroid (at least 1000ug beclomethasone dipropionate or equivalent) and a regular inhaled long acting B-2 agonist for at least 3 months prior to screening and prior to at least two independent asthma exacerbations requiring unscheduled clinical intervention with a systemic corticosteroid in the past year or the severe asthma exacerbation requiring the hospitalization/ER visit.
- •who are receiving an ICS dosage > 1000ug beclomethasone dipropionate or equivalent and a regular inhaled long acting B-2 agonist for the last 4 weeks of the run-in period and at randomization (to be maintained throughout the study).
- •whose asthma medication remains unchanged in the final 4 weeks of the run-in period (to be maintained throughout the study).
- •with evidence of poor asthma symptom control at screening (based on patient history) and during the 4 weeks immediately prior to baseline.
排除标准
- 未提供
结局指标
主要结局
Clinically significant asthma exacerbation
次要结局
- Quality of Life assessment at baseline, last visit
- Medical resource utilization
- Time to first asthma exacerbation
- Frequency of asthma rescue medication use
- Safety/tolerability of omalizumab
研究者
相似试验
已完成
3 期
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsNasal PolypsChronic RhinosinusitisNCT03280550Hoffmann-La Roche138
已完成
3 期
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal PolypsNasal PolypsChronic RhinosinusitisNCT03280537Hoffmann-La Roche127
已完成
3 期
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyPersistent Allergic AsthmaNCT01202903Novartis Pharmaceuticals616
已完成
不适用
Clinical effects of treatment with omalizumab in patients with asthmaBronchial asthmaJPRN-UMIN000002765Atami Hospital International University of Health and Welfare40
已完成
3 期
Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsSeasonal Allergic RhinitisNCT03369704Novartis Pharmaceuticals337